The drug maker even has plans to bring differentiated products based on novel drug delivery systems, biosimilars and specialty drugs from its portfolio. The $2 billion company by revenue promoted by NRI entrepreneur brothers Chirag Patel and Chintu Patel, has begun commercial operations in India in August with the launch of hospital or critical care division with 120 people, and 30 products.
